Abstract
Head and neck squamous cell carcinoma (HNSCC) remains a significant clinical challenge due to high rates of recurrence and metastasis, often driven by cancer stem-like cells (CSCs). This study identifies Lysosomal Integral Membrane Protein-2 (LIMP-2) as a critical driver of CSC properties. LIMP-2 promotes the autophagy-mediated degradation of GSK3β, thereby preventing the breakdown of β-catenin and activating Wnt signaling pathways. Functional assays demonstrate that LIMP-2 overexpression enhances colony and tumor sphere formation, effects that are abolished by β-catenin knockdown. This correction addresses an error in the representation of functional rescue data, reaffirming the study's original conclusions.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is characterized by a subpopulation of cells known as cancer stem-like cells (CSCs), which possess self-renewal capabilities and resistance to standard therapies. Understanding the molecular mechanisms that maintain these "stem-like" properties is crucial for developing effective treatments. This research investigates the role of LIMP-2, a protein typically associated with lysosomal function, and its crosstalk with the Wnt/β-catenin pathway—a well-known regulator of cell fate and stemness.
Methods
The study utilized bioinformatic analysis of the TCGA-HNSCC dataset to link LIMP-2 expression with Wnt pathway genes. In vitro experiments were conducted using 4MOSC1 and 4MOSC2 cell lines. Genetic manipulation involved LIMP-2 overexpression (OE-LIMP-2) and knockdown (shLIMP-2 or siRNA against β-catenin). Functional impacts were assessed through Western blotting for CSC markers (CD44, ALDH1, CD133) and signaling proteins, CCK-8 proliferation assays, and colony/tumor sphere formation assays. Subcellular fractionation was used to track the nuclear localization of signaling proteins.
Results and Discussion
The LIMP-2/Autophagy/GSK3β Axis
A key finding of this study is that LIMP-2 actively promotes the autophagy-induced degradation of GSK3β. In normal cellular conditions, GSK3β acts as a negative regulator of the Wnt pathway by targeting β-catenin for degradation. By facilitating the removal of GSK3β, LIMP-2 allows β-catenin to accumulate and translocate into the nucleus, where it drives the expression of genes associated with stemness and proliferation.
Western blot analysis confirmed that LIMP-2 overexpression leads to a marked increase in CSC markers, including CD44, ALDH1, and CD133. Conversely, LIMP-2 knockdown reduced these markers along with mesenchymal markers like Vimentin and N-cadherin, suggesting a broader role in epithelial-mesenchymal transition (EMT).
Functional Impact and Rescue via β-catenin
Functional assays further validated the oncogenic role of LIMP-2. Overexpression significantly increased both the number of colonies and the efficiency of tumor sphere formation in HNSCC cell lines. Crucially, these pro-cancer effects were found to be dependent on β-catenin. When β-catenin was silenced using siRNA (si-β-catenin), the boost in stemness and proliferation caused by LIMP-2 overexpression was effectively abolished.
The specific correction in this report pertains to the visual representation of these rescue experiments (specifically Supplementary Fig. 7f). The authors replaced the image for the "OE-LIMP-2 + si-β-catenin" group to accurately reflect the experimental findings. This correction reinforces the conclusion that the LIMP-2/β-catenin axis is a primary driver of the observed CSC phenotype.
Conclusion
This research highlights the role of lysosomes as sophisticated signaling hubs rather than mere degradative organelles. LIMP-2 emerges as a potential therapeutic target in HNSCC, although pharmacologically inhibiting a lysosomal membrane protein without off-target toxicity remains a challenge. Future work should focus on the exact molecular bridge between LIMP-2 and GSK3β-specific autophagy and validate these findings in in vivo models.
Summary updated